Quantcast

Latest Veltuzumab Stories

2014-03-06 16:27:44

SAN DIEGO and MORRIS PLAINS, N.J., March 6, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Immunomedics, Inc. (NASDAQ: IMMU) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities and Exchange Act of 1934 between May 9, 2013 and October 9, 2013 (the "Class Period")....

2010-06-16 08:30:00

ATLANTA, June 16 /PRNewswire-FirstCall/ -- UCB (Euronext: UCB) and Immunomedics, Inc. (Nasdaq: IMMU) announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Data presented at the European League Against Rheumatism (EULAR) meeting in Rome from the phase IIb study, EMBLEM(TM), suggest promising results of epratuzumab in patients with SLE. EMBLEM(TM) was a 12-week,...

2009-01-20 07:30:00

SAN FRANCISCO, Jan. 20 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that results presented at the 2009 Gastrointestinal Cancers Symposium showed that labetuzumab-SN-38, an antibody-drug conjugate, selectively delivers SN-38 to human colon carcinoma in animal models as an effective new therapy. SN-38 is the active metabolite of irinotecan, a...

2009-01-07 10:11:00

MORRIS PLAINS, N.J., Jan. 7 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that Cynthia L. Sullivan, President and Chief Executive Officer, will be presenting at the 27th Annual J.P. Morgan Healthcare Conference to be held in San Francisco, CA. Ms. Sullivan's presentation, which is scheduled for Thursday, January 15th at 1:30 p.m., will provide a...

2008-11-11 09:00:47

MORRIS PLAINS, N.J., Nov. 11, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that Gerard G. Gorman, Senior Vice President, Finance and Business Development, and Chief Financial Officer, will be presenting at the Lazard Capital Markets 5th Annual Healthcare Conference to be held in New York City from November 18 - 19, 2008. Mr. Gorman's presentation,...

2008-11-07 09:00:25

MORRIS PLAINS, N.J., Nov. 7, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported revenues of $4.9 million and a net loss of $2.2 million, or $0.03 per share, for the first quarter of fiscal year 2009, which ended September 30, 2008. This compares to revenues of $0.8 million and a net loss of $4.6 million, or $0.06 per share, for the same period last year....

2008-10-30 09:00:41

MORRIS PLAINS, N.J., Oct. 30, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that Cynthia L. Sullivan, President and Chief Executive Officer, will provide a corporate overview at the Oppenheimer 19th Annual Healthcare Conference in New York. The presentation, scheduled on November 4, 2008 at 4:00 p.m., can be downloaded simultaneously at...

2008-10-15 12:00:34

Immunomedics, a biopharmaceutical company, has received a new US patent that covers the composition of matter and the use of humanized, chimeric and human anti-CD20 antibodies and antibody fusion proteins or fragments thereof comprising at least the veltuzumab antibody that targets the CD20 antigen present on B-lymphocytes, leukemias, and lymphomas. The allowed claims cover the use of veltuzumab and bispecific antibody protein constructs for the treatment and diagnosis of B-cell disorders,...

2008-10-14 09:00:11

MORRIS PLAINS, N.J., Oct. 14, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced that U.S. patent 7,435,803 was issued today covering the composition of matter and the use of humanized, chimeric and human anti-CD20 antibodies and antibody fusion proteins or fragments thereof comprising at least the veltuzumab antibody that targets the CD20 antigen present on...

2008-09-17 12:00:11

MORRIS PLAINS, N.J., Sept. 17, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today provided a detailed review and update of the Company's clinical pipeline, including plans for future clinical and research developments at the Company's Research and Development Day held at the Waldorf Astoria Hotel in New York City. An archived version of today's webcast will be...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related